Trial Profile
Cubicin(R) for Complicated Post-surgical Wound Infections
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 13 Dec 2023
Price :
$35
*
At a glance
- Drugs Daptomycin (Primary)
- Indications Gram-positive infections; Skin and soft tissue infections; Surgical wound infections
- Focus Therapeutic Use
- Sponsors Cubist Pharmaceuticals
- 23 Apr 2008 New trial record.